Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Jan;79(927):5–10. doi: 10.1136/pmj.79.927.5

Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis

S Pastores 1
PMCID: PMC1742596  PMID: 12566544

Abstract

Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In patients with sepsis, endogenous protein C levels are decreased, shifting the balance toward greater systemic inflammation, coagulation, and cell death. On the basis of a single large randomised phase 3 trial, drotrecogin alfa (activated), a recombinant form of human activated protein C, was recently approved for the treatment of adult patients with severe sepsis and a high risk of death. Since its approval, several questions have been raised regarding the appropriate use of this agent. Given the increased risk of serious bleeding and the high cost of treatment, drotrecogin alfa (activated) should be reserved at this time for the most acutely ill patients with severe sepsis who meet the criteria that were used in the phase 3 trial.

Full Text

The Full Text of this article is available as a PDF (143.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000 Sep;28(9 Suppl):S31–S33. doi: 10.1097/00003246-200009001-00007. [DOI] [PubMed] [Google Scholar]
  2. Alberio L., Lämmle B., Esmon C. T. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis. 2001 Apr 9;32(9):1338–1346. doi: 10.1086/319995. [DOI] [PubMed] [Google Scholar]
  3. Angus D. C., Linde-Zwirble W. T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303–1310. doi: 10.1097/00003246-200107000-00002. [DOI] [PubMed] [Google Scholar]
  4. Annane Djillali, Sébille Véronique, Charpentier Claire, Bollaert Pierre-Edouard, François Bruno, Korach Jean-Michel, Capellier Gilles, Cohen Yves, Azoulay Elie, Troché Gilles. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862–871. doi: 10.1001/jama.288.7.862. [DOI] [PubMed] [Google Scholar]
  5. Bernard G. R., Ely E. W., Wright T. J., Fraiz J., Stasek J. E., Jr, Russell J. A., Mayers I., Rosenfeld B. A., Morris P. E., Yan S. B. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001 Nov;29(11):2051–2059. doi: 10.1097/00003246-200111000-00003. [DOI] [PubMed] [Google Scholar]
  6. Bernard G. R., Vincent J. L., Laterre P. F., LaRosa S. P., Dhainaut J. F., Lopez-Rodriguez A., Steingrub J. S., Garber G. E., Helterbrand J. D., Ely E. W. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699–709. doi: 10.1056/NEJM200103083441001. [DOI] [PubMed] [Google Scholar]
  7. Bone R. C., Grodzin C. J., Balk R. A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997 Jul;112(1):235–243. doi: 10.1378/chest.112.1.235. [DOI] [PubMed] [Google Scholar]
  8. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., Mercier J. C., Offenstadt G., Régnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995 Sep 27;274(12):968–974. [PubMed] [Google Scholar]
  9. Corrigan J. J., Jr, Ray W. L., May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med. 1968 Oct 17;279(16):851–856. doi: 10.1056/NEJM196810172791603. [DOI] [PubMed] [Google Scholar]
  10. Cunningham M. A., Romas P., Hutchinson P., Holdsworth S. R., Tipping P. G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999 Nov 15;94(10):3413–3420. [PubMed] [Google Scholar]
  11. Deveraux Q. L., Reed J. C. IAP family proteins--suppressors of apoptosis. Genes Dev. 1999 Feb 1;13(3):239–252. doi: 10.1101/gad.13.3.239. [DOI] [PubMed] [Google Scholar]
  12. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost. 1998;24(1):61–69. doi: 10.1055/s-2007-995824. [DOI] [PubMed] [Google Scholar]
  13. Dreyfus M., Magny J. F., Bridey F., Schwarz H. P., Planché C., Dehan M., Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991 Nov 28;325(22):1565–1568. doi: 10.1056/NEJM199111283252207. [DOI] [PubMed] [Google Scholar]
  14. Ely E. Wesley, Bernard Gordon R., Vincent Jean-Louis. Activated protein C for severe sepsis. N Engl J Med. 2002 Sep 26;347(13):1035–1036. doi: 10.1056/NEJM200209263471315. [DOI] [PubMed] [Google Scholar]
  15. Esmon C. T., Ding W., Yasuhiro K., Gu J. M., Ferrell G., Regan L. M., Stearns-Kurosawa D. J., Kurosawa S., Mather T., Laszik Z. The protein C pathway: new insights. Thromb Haemost. 1997 Jul;78(1):70–74. [PubMed] [Google Scholar]
  16. Ettingshausen C. E., Veldmann A., Beeg T., Schneider W., Jäger G., Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost. 1999;25(6):537–541. doi: 10.1055/s-2007-994962. [DOI] [PubMed] [Google Scholar]
  17. Faust S. N., Levin M., Harrison O. B., Goldin R. D., Lockhart M. S., Kondaveeti S., Laszik Z., Esmon C. T., Heyderman R. S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001 Aug 9;345(6):408–416. doi: 10.1056/NEJM200108093450603. [DOI] [PubMed] [Google Scholar]
  18. Fijnvandraat K., Derkx B., Peters M., Bijlmer R., Sturk A., Prins M. H., van Deventer S. J., ten Cate J. W. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost. 1995 Jan;73(1):15–20. [PubMed] [Google Scholar]
  19. Fisher C. J., Jr, Yan S. B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 2000 Sep;28(9 Suppl):S49–S56. doi: 10.1097/00003246-200009001-00011. [DOI] [PubMed] [Google Scholar]
  20. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., Marey A., Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992 Mar;101(3):816–823. doi: 10.1378/chest.101.3.816. [DOI] [PubMed] [Google Scholar]
  21. Freeman B. D., Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs. 2000 Jul;9(7):1651–1663. doi: 10.1517/13543784.9.7.1651. [DOI] [PubMed] [Google Scholar]
  22. Freeman Bradley D., Buchman Timothy G. Coagulation inhibitors in the treatment of sepsis. Expert Opin Investig Drugs. 2002 Jan;11(1):69–74. doi: 10.1517/13543784.11.1.69. [DOI] [PubMed] [Google Scholar]
  23. Friedman G., Silva E., Vincent J. L. Has the mortality of septic shock changed with time. Crit Care Med. 1998 Dec;26(12):2078–2086. doi: 10.1097/00003246-199812000-00045. [DOI] [PubMed] [Google Scholar]
  24. Gerson W. T., Dickerman J. D., Bovill E. G., Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics. 1993 Feb;91(2):418–422. [PubMed] [Google Scholar]
  25. Gordon B., Haire W., Ruby E., Stephens L., Kotulak G., Kessinger A. Prolonged deficiency of protein C following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996 Mar;17(3):415–419. [PubMed] [Google Scholar]
  26. Grinnell B. W., Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med. 2001 Jul;29(7 Suppl):S53–S61. doi: 10.1097/00003246-200107001-00020. [DOI] [PubMed] [Google Scholar]
  27. Haire W. D., Ruby E. I., Gordon B. G., Patil K. D., Stephens L. C., Kotulak G. D., Reed E. C., Vose J. M., Bierman P. J., Kessinger A. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995 Oct 25;274(16):1289–1295. [PubMed] [Google Scholar]
  28. Healy Daniel P. New and emerging therapies for sepsis. Ann Pharmacother. 2002 Apr;36(4):648–654. doi: 10.1345/aph.1A283. [DOI] [PubMed] [Google Scholar]
  29. Herbert J. M., Dupuy E., Laplace M. C., Zini J. M., Bar Shavit R., Tobelem G. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J. 1994 Oct 1;303(Pt 1):227–231. doi: 10.1042/bj3030227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hinshaw L. B. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med. 1996 Jun;24(6):1072–1078. doi: 10.1097/00003246-199606000-00031. [DOI] [PubMed] [Google Scholar]
  31. Iba T., Kidokoro A., Yagi Y. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg. 1998 Sep;187(3):321–329. doi: 10.1016/s1072-7515(98)00177-x. [DOI] [PubMed] [Google Scholar]
  32. Jones A., Geczy C. L. Thrombin and factor Xa enhance the production of interleukin-1. Immunology. 1990 Oct;71(2):236–241. [PMC free article] [PubMed] [Google Scholar]
  33. Joyce D. E., Gelbert L., Ciaccia A., DeHoff B., Grinnell B. W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001 Feb 5;276(14):11199–11203. doi: 10.1074/jbc.C100017200. [DOI] [PubMed] [Google Scholar]
  34. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818–829. [PubMed] [Google Scholar]
  35. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999 Aug 19;341(8):586–592. doi: 10.1056/NEJM199908193410807. [DOI] [PubMed] [Google Scholar]
  36. Lorente J. A., García-Frade L. J., Landín L., de Pablo R., Torrado C., Renes E., García-Avello A. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993 May;103(5):1536–1542. doi: 10.1378/chest.103.5.1536. [DOI] [PubMed] [Google Scholar]
  37. Manns Braden J., Lee Helen, Doig Christopher James, Johnson David, Donaldson Cam. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002 Sep 26;347(13):993–1000. doi: 10.1056/NEJMsa020969. [DOI] [PubMed] [Google Scholar]
  38. Matthay M. A. Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001 Mar 8;344(10):759–762. doi: 10.1056/NEJM200103083441009. [DOI] [PubMed] [Google Scholar]
  39. Mesters R. M., Helterbrand J., Utterback B. G., Yan B., Chao Y. B., Fernandez J. A., Griffin J. H., Hartman D. L. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med. 2000 Jul;28(7):2209–2216. doi: 10.1097/00003246-200007000-00005. [DOI] [PubMed] [Google Scholar]
  40. Mesters R. M., Mannucci P. M., Coppola R., Keller T., Ostermann H., Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996 Aug 1;88(3):881–886. [PubMed] [Google Scholar]
  41. Natanson C., Esposito C. J., Banks S. M. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med. 1998 Dec;26(12):1927–1931. doi: 10.1097/00003246-199812000-00001. [DOI] [PubMed] [Google Scholar]
  42. Opal S. M., Cross A. S. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am. 1999 Jun;13(2):285-97, vii. doi: 10.1016/s0891-5520(05)70075-1. [DOI] [PubMed] [Google Scholar]
  43. Osterud B., Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 1983 Feb 28;49(1):5–7. [PubMed] [Google Scholar]
  44. Padkin A., Rowan K., Black N. Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C. BMJ. 2001 Oct 20;323(7318):923–926. doi: 10.1136/bmj.323.7318.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Parent C., Eichacker P. Q. Neutrophil and endothelial cell interactions in sepsis. The role of adhesion molecules. Infect Dis Clin North Am. 1999 Jun;13(2):427-47, x. doi: 10.1016/s0891-5520(05)70084-2. [DOI] [PubMed] [Google Scholar]
  46. Parrillo J. E. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20;328(20):1471–1477. doi: 10.1056/NEJM199305203282008. [DOI] [PubMed] [Google Scholar]
  47. Rintala E., Seppälä O. P., Kotilainen P., Pettilä V., Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med. 1998 May;26(5):965–968. doi: 10.1097/00003246-199805000-00038. [DOI] [PubMed] [Google Scholar]
  48. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M., Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368–1377. doi: 10.1056/NEJMoa010307. [DOI] [PubMed] [Google Scholar]
  49. Sands K. E., Bates D. W., Lanken P. N., Graman P. S., Hibberd P. L., Kahn K. L., Parsonnet J., Panzer R., Orav E. J., Snydman D. R. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997 Jul 16;278(3):234–240. [PubMed] [Google Scholar]
  50. Smith O. P., White B., Vaughan D., Rafferty M., Claffey L., Lyons B., Casey W. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997 Nov 29;350(9091):1590–1593. doi: 10.1016/s0140-6736(97)06356-3. [DOI] [PubMed] [Google Scholar]
  51. Taylor F. B., Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987 Mar;79(3):918–925. doi: 10.1172/JCI112902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Taylor F. B., Jr, Chang A., Ruf W., Morrissey J. H., Hinshaw L., Catlett R., Blick K., Edgington T. S. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991 Mar;33(3):127–134. [PubMed] [Google Scholar]
  53. Vervloet M. G., Thijs L. G., Hack C. E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24(1):33–44. doi: 10.1055/s-2007-995821. [DOI] [PubMed] [Google Scholar]
  54. Warren B. L., Eid A., Singer P., Pillay S. S., Carl P., Novak I., Chalupa P., Atherstone A., Pénzes I., Kübler A. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001 Oct 17;286(15):1869–1878. doi: 10.1001/jama.286.15.1869. [DOI] [PubMed] [Google Scholar]
  55. Wheeler A. P., Bernard G. R. Treating patients with severe sepsis. N Engl J Med. 1999 Jan 21;340(3):207–214. doi: 10.1056/NEJM199901213400307. [DOI] [PubMed] [Google Scholar]
  56. White B., Livingstone W., Murphy C., Hodgson A., Rafferty M., Smith O. P. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000 Dec 1;96(12):3719–3724. [PubMed] [Google Scholar]
  57. Yan S. C., Razzano P., Chao Y. B., Walls J. D., Berg D. T., McClure D. B., Grinnell B. W. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology (N Y) 1990 Jul;8(7):655–661. doi: 10.1038/nbt0790-655. [DOI] [PubMed] [Google Scholar]
  58. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 Dec 15;76(12):2520–2526. [PubMed] [Google Scholar]
  59. van der Poll T., Büller H. R., ten Cate H., Wortel C. H., Bauer K. A., van Deventer S. J., Hack C. E., Sauerwein H. P., Rosenberg R. D., ten Cate J. W. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990 Jun 7;322(23):1622–1627. doi: 10.1056/NEJM199006073222302. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES